A drug called zanzalintinib for children and teens with solid tumors that came back
Original title: Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test to find a safe dose in young people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing how safe a drug called zanzalintinib is for young people with cancer.
Who this trial is for. This trial is for children and teens whose solid tumors came back or kept growing. It tests a drug called zanzalintinib.
Where it stands. The trial has not reported results. The team wants to find the highest dose young people can take safely. They are also watching for side effects. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If your child has a solid tumor that came back, this may be worth asking about. Their care team can tell you if this study could be a fit.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, August 19, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.